https://www.renbio.com/news_and_events/renbio-announces-new-awards-to-support-continued-development-of-its-novel-dna-based-myo-technologytm-platform-for-antiviral-applications/

The flexibility
to go further

the representation of a cell

MYO Technology is superior

Traditional protein therapeutic treatments require large doses of short acting medicine, and also suffer from high costs of production and cold chain logistics. MYO Technology removes these hurdles with long-lasting, less-frequent, more streamlined treatment regimens without the logistical hurdles of cold chain management and long, costly, manufacturing processes.

Clinical Applications

Blood disorders icon
Inflammatory diseases icon
Viral infections